RNTX
Rein Therapeutics Inc
0.8007$
-6.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +726.8% | -6.4% | +10.3% | -4.7% | -40.3% | -7.3% | -0.3% | -6.6% | -55.0% | +8.8% | +151.0% | |
| – | +42.8% | -30.1% | +81.4% | -19.3% | -26.9% | -39.0% | -20.8% | -21.6% | -16.4% | +26.1% | +660.2% | |
| – | +43.5% | -30.4% | +82.0% | -19.5% | -27.1% | -42.3% | -23.0% | -29.3% | -20.6% | +38.3% | +92.2% | |
| – | +43.5% | -30.4% | +82.0% | -19.5% | -27.1% | -42.3% | -23.0% | -29.3% | -20.6% | +38.3% | +814.4% | |
| – | – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | – | +0.0% | +0.0% | +0.0% | -46.7% | +0.0% | +0.0% | +0.0% | -68.0% | +0.0% | +0.0% | |
| – | +6,003.5% | -45.1% | -1.9% | +1.1% | -85.6% | +576.5% | +3.3% | -86.2% | -3.7% | +103.0% | +279.5% | |
| – | +170.0% | +3.4% | +8.9% | +14.6% | +1.6% | +4.0% | +28.7% | -25.3% | +7.6% | +120.7% | -28.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +145.9% | +81.2% | -63.7% | +38.0% | -15.6% | +26.1% | +424.6% | -31.6% | -3.6% | +57.5% | -28.7% | |
| – | -38.5% | +549.8% | +25.2% | -10.3% | +8.3% | -91.0% | -38.3% | +1,435.6% | -63.4% | -31.5% | -12.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.0% | +74.1% | +139.9% | +8.8% | -99.9% | +105,649.6% | +5.4% | +9.0% | -3.5% | +19.3% | +0.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.